HomeCompareICPVF vs ABBV

ICPVF vs ABBV: Dividend Comparison 2026

ICPVF yields 3.76% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICPVF wins by $1303.05M in total portfolio value· pulled ahead in Year 2
10 years
ICPVF
ICPVF
● Live price
3.76%
Share price
$2.06
Annual div
$0.08
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1303.15M
Annual income
$1,239,798,671.25
Full ICPVF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ICPVF vs ABBV

📍 ICPVF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICPVFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICPVF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICPVF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICPVF
Annual income on $10K today (after 15% tax)
$319.56/yr
After 10yr DRIP, annual income (after tax)
$1,053,828,870.56/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ICPVF beats the other by $1,053,807,814.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICPVF + ABBV for your $10,000?

ICPVF: 50%ABBV: 50%
100% ABBV50/50100% ICPVF
Portfolio after 10yr
$651.63M
Annual income
$619,911,721.51/yr
Blended yield
95.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ICPVF
No analyst data
Altman Z
2.2
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICPVF buys
0
ABBV buys
0
No recent congressional trades found for ICPVF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICPVFABBV
Forward yield3.76%3.06%
Annual dividend / share$0.08$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$1303.15M$102.3K
Annual income after 10y$1,239,798,671.25$24,771.77
Total dividends collected$1298.59M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ICPVF vs ABBV ($10,000, DRIP)

YearICPVF PortfolioICPVF Income/yrABBV PortfolioABBV Income/yrGap
1$11,452$751.91$11,550$430.00$98.00ABBV
2← crossover$13,863$1,609.50$13,472$627.96+$391.00ICPVF
3$18,475$3,641.83$15,906$926.08+$2.6KICPVF
4$28,840$9,071.89$19,071$1,382.55+$9.8KICPVF
5$57,329$26,470.06$23,302$2,095.81+$34.0KICPVF
6$159,693$98,350.37$29,150$3,237.93+$130.5KICPVF
7$682,943$512,071.39$37,536$5,121.41+$645.4KICPVF
8$4,824,069$4,093,320.04$50,079$8,338.38+$4.77MICPVF
9$59,206,211$54,044,457.59$69,753$14,065.80+$59.14MICPVF
10$1,303,149,317$1,239,798,671.25$102,337$24,771.77+$1303.05MICPVF

ICPVF vs ABBV: Complete Analysis 2026

ICPVFStock

Dyno Nobel Limited, together with its subsidiaries, manufactures and distributes commercial explosives in in the United States, Australia, and Mexico. It offers packaged explosives, including Powermite, a cartridge explosive; and Dynosplit for pre-split applications, as well as ammonium nitrates. The company sells industrial explosives and related products and services to metal/mineral mining; quarrying; agriculture and industrial; oil and gas exploration; and concrete and building material industries. It also exports its products.

Full ICPVF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ICPVF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICPVF vs SCHDICPVF vs JEPIICPVF vs OICPVF vs KOICPVF vs MAINICPVF vs JNJICPVF vs MRKICPVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.